ProShares Ultra NASDAQ Biotechnology
BIB
24 hedge funds and large institutions have $19.4M invested in ProShares Ultra NASDAQ Biotechnology in 2015 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 11 closing their positions.
11% less funds holding
Funds holding: 27 → 24 (-3)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
47% less capital invested
Capital invested by funds: $36.3M → $19.4M (-$16.9M)
51% less call options, than puts
Call options by funds: $24.9M | Put options by funds: $51.2M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$4.73M |
| 2 |
AIG
American International Group
New York
|
+$1.64M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$844K |
| 4 |
WSTAM
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
|
+$694K |
| 5 |
BHA
Beech Hill Advisors
New York
|
+$639K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AP
Advisors Preferred
Rockville,
Maryland
|
-$6.46M |
| 2 |
PCM
Prelude Capital Management
New York
|
-$2.48M |
| 3 |
OPPM
Opus Point Partners Management
New York
|
-$1.78M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.34M |
| 5 |
Jane Street
New York
|
-$626K |
BIB Hedge Fund Activity: Q3 2015 in Review
24 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2015, worth a combined $19.4M — down 47% from $36.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of BIB and 8 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $4.73M. The largest seller was Advisors Preferred, exiting entirely with an estimated $6.46M sold.
- 24 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2015, down from 27 in Q2 2015.
- Funds reported $19.4M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2015, down 47% quarter-over-quarter.
- 8 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2015 and 11 closed out, a net change of -3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2015 was Virtu Financial, an estimated $4.73M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2015 was Advisors Preferred, an estimated $6.46M sold.
Based on aggregated 13F filings for Q3 2015.